EUVIMEDEUVIMED entdecken
Crossref

International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder

Heval Özgen, Renske Spijkerman, Moritz Noack, Martin Holtmann, Arnt S A Schellekens, Geurt van de Glind, Tobias Banaschewski, Csaba Barta, Alex Begeman, Miguel Casas, Cleo L Crunelle, Constanza Daigre Blanco und 43 weitere

European Addiction Research · 2020 · 26 (4-5) · 223-232

DOI: 10.1159/000508385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Addiction Research, online erschienen am 07.07.2020. Verfasst von Heval Özgen und 54 weiteren Autor:innen. Beteiligte Einrichtung: Parnassia Addiction Research Centre (PARC), Parnassia Psychiatric Institute, The Hague, The Netherlands, m.h.ozgen@parnassiagroep.nl. Hauptthemen laut MEDLINE: Consensus, Evidence-Based Practice, Mass Screening, Substance-Related Disorders. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Childhood attention-deficit/hyperactivity disorder (ADHD) is a risk factor for substance misuse and substance use disorder (SUD) in adolescence and (early) adulthood. ADHD and SUD also frequently co-occur in treatment-seeking adolescents, which complicates diagnosis and treatment and is associated with poor treatment outcomes. Research on the effect of treatment of childhood ADHD on the prevention of adolescent SUD is inconclusive, and studies on the diagnosis and treatment of adolescents with ADHD and SUD are scarce. Thus, the available evidence is generally not sufficient to justify robust treatment recommendations.

Objective

The aim of the study was to obtain a consensus statement based on a combination of scientific data and clinical experience.

Method

A modified Delphi study to reach consensus based upon the combination of scientific data and clinical experience with a multidisciplinary group of 55 experts from 17 countries. The experts were asked to rate a set of statements on the effect of treatment of childhood ADHD on adolescent SUD and on the screening, diagnosis, and treatment of adolescents with comorbid ADHD and SUD.

Results

After 3 iterative rounds of rating and adapting 37 statements, consensus was reached on 36 of these statements representing 6 domains: general (n = 4), risk of developing SUD (n = 3), screening and diagnosis (n = 7), psychosocial treatment (n = 5), pharmacological treatment (n = 11), and complementary treatments (n = 7). Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings. Long-acting stimulants are recommended as the first-line treatment of ADHD in adolescents with concurrent ADHD and SUD, and pharmacotherapy should preferably be embedded in psychosocial treatment. The only remaining no-consensus statement concerned the requirement of abstinence before starting pharmacological treatment in adolescents with ADHD and concurrent SUD. In contrast to the majority, some experts required full abstinence before starting any pharmacological treatment, some were against the use of stimulants in the treatment of these patients (independent of abstinence), while some were against the alternative use of bupropion.

Conclusion

This international consensus statement can be used by clinicians and patients together in a shared decision-making process to select the best interventions and to reach optimal outcomes in adolescent patients with concurrent ADHD and SUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConsensusEvidence-Based PracticeMass ScreeningSubstance-Related DisordersAdolescentAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsDelphi TechniqueFemaleGlobal HealthHumansMaleRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

AdolescentsAttention-deficit/hyperactivity disorderConsensus statementSubstance use disorder

Substanzen

Central Nervous System Stimulants

Autor:innen und Institutionen

  • Parnassia Addiction Research Centre (PARC), Parnassia Psychiatric Institute, The Hague, The Netherlands, m.h.ozgen@parnassiagroep.nl.
  • Curium, Department of Child and Adolescent Psychiatry, Leiden University Medical Center, Leiden, The Netherlands, m.h.ozgen@parnassiagroep.nl.
  • Parnassia Addiction Research Centre (PARC), Parnassia Psychiatric Institute, The Hague, The Netherlands.
  • Department of Child and Adolescent Psychiatry, LWL-University Hospital, Ruhr-University Bochum, Hamm, Germany.
  • Department of Psychiatry, Donders institute, RadboudUMC, Nijmegen, The Netherlands.
  • Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), RadboudUMC, Nijmegen, The Netherlands.

Zitieren

APA

Özgen, H., Spijkerman, R., Noack, M., Holtmann, M., Schellekens, A. S. A., van de Glind, G., Banaschewski, T., Barta, C., Begeman, A., Casas, M., Crunelle, C. L., Daigre Blanco, C., Dalsgaard, S., Demetrovics, Z., den Boer, J., Dom, G., Eapen, V., Faraone, S. V., Franck, J., …, & Hendriks, V. (2020). International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. European Addiction Research, 26(4-5), 223-232. https://doi.org/10.1159/000508385

Vancouver

Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van de Glind G, et al. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. European Addiction Research. 2020;26(4-5):223-232. doi:10.1159/000508385

BibTeX
@article{zgen2020,
  author = {Özgen, Heval and Spijkerman, Renske and Noack, Moritz and Holtmann, Martin and Schellekens, Arnt S A and van de Glind, Geurt and Banaschewski, Tobias and Barta, Csaba and Begeman, Alex and Casas, Miguel and Crunelle, Cleo L and Daigre Blanco, Constanza and Dalsgaard, Søren and Demetrovics, Zsolt and den Boer, Jacomine and Dom, Geert and Eapen, Valsamma and Faraone, Stephen V and Franck, Johan and González, Rafael A and Grau-López, Lara and Groenman, Annabeth P and Hemphälä, Malin and Icick, Romain and Johnson, Brian and Kaess, Michael and Kapitány-Fövény, Máté and Kasinathan, John G and Kaye, Sharlene S and Kiefer, Falk and Konstenius, Maija and Levin, Frances R and Luderer, Mathias and Martinotti, Giovanni and Matthys, Frieda I A and Meszaros, Gergely and Moggi, Franz and Munasur-Naidoo, Ashmita P and Post, Marianne and Rabinovitz, Sharon and Ramos-Quiroga, J Antoni and Sala, Regina and Shafi, Abu and Slobodin, Ortal and Staal, Wouter G and Thomasius, Rainer and Truter, Ilse and van Kernebeek, Michiel W and Velez-Pastrana, Maria C and Vollstädt-Klein, Sabine and Vorspan, Florence and Young, Jesse T and Yule, Amy and van den Brink, Wim and Hendriks, Vincent},
  title = {International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder},
  journal = {European Addiction Research},
  year = {2020},
  volume = {26},
  number = {4-5},
  pages = {223--232},
  doi = {10.1159/000508385}
}
Kostenlos starten →